{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Sales CS"],"pubmed_abstract":["<h4>Purpose</h4>The aim of this study was to report the 1-week and 6-month refractive outcomes of eyes treated with a novel silicone corneal shield designed to improve visual recovery after photorefractive keratectomy (PRK).<h4>Patients and methods</h4>This prospective, observational clinical trial recruited 45 myopic eyes with or without astigmatism at a university eye clinic to undergo wavefront-guided PRK followed by application of an investigational silicone corneal shield that was removed on postoperative day 4. The primary outcome measures were efficacy, predictability, and safety at the 6-month visit. The secondary end points included short-term uncorrected distance visual acuity (UDVA) and pain.<h4>Results</h4>No adverse outcomes occurred using the device. At 6 months, 79.5% of eye"],"journal":["Clinical ophthalmology (Auckland, N.Z.)"],"pagination":["115-121"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6327892"],"repository":["biostudies-literature"],"pubmed_title":["Prospective evaluation of a novel silicone corneal shield after PRK: 6-month efficacy, safety, and predictability outcomes."],"pmcid":["PMC6327892"],"pubmed_authors":["Manche EE","Sales CS"],"additional_accession":[]},"is_claimable":false,"name":"Prospective evaluation of a novel silicone corneal shield after PRK: 6-month efficacy, safety, and predictability outcomes.","description":"<h4>Purpose</h4>The aim of this study was to report the 1-week and 6-month refractive outcomes of eyes treated with a novel silicone corneal shield designed to improve visual recovery after photorefractive keratectomy (PRK).<h4>Patients and methods</h4>This prospective, observational clinical trial recruited 45 myopic eyes with or without astigmatism at a university eye clinic to undergo wavefront-guided PRK followed by application of an investigational silicone corneal shield that was removed on postoperative day 4. The primary outcome measures were efficacy, predictability, and safety at the 6-month visit. The secondary end points included short-term uncorrected distance visual acuity (UDVA) and pain.<h4>Results</h4>No adverse outcomes occurred using the device. At 6 months, 79.5% of eye","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019","modification":"2025-05-29T14:36:58.68Z","creation":"2025-05-29T14:36:58.68Z"},"accession":"S-EPMC6327892","cross_references":{"pubmed":["30662255"],"doi":["10.2147/OPTH.S183120"]}}